United Therapeutics saw an improvement in its IBD SmartSelect Composite Rating Monday, from 94 to 96.
Looking For The Best Stocks To Buy And Watch? Start Here
The new rating shows the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria.
United Therapeutics is not currently near a proper buy point. See if the stock goes on to form a new chart pattern and offer a new buying opportunity.
The stock sports an 84 EPS Rating, meaning its recent quarterly and annual earnings growth tops 84% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q2, the company posted 10% earnings growth. Sales growth came in at 12%, down from 17% in the previous quarter.
United Therapeutics earns the No. 11 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
